Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity
Contraindications It is not recommended for use in people with certain skin conditions or disorders, due to insufficient safety data
[8] Intranasal Peptide Administration Intranasal administration can bypass some aspects of gastrointestinal degradation by exploiting the nasal mucosa for absorption
The RxPepsDirect starting dose is 20 units (0.6 mg) per injection on a U-100 syringe drawn from a 15 mg/3 mL vial
The gutbrain axis in appetite, satiety, food intake, and eating behavior: insights from animal models and human studies
Instead, alternate morning/evening or use them on non-exfoliation days